Hypoglycemia in People with Type 2 Diabetes and CKD
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background and objectives: Among people with diabetes mellitus, CKD may promote hypoglycemia through altered clearance of glucose-lowering medications, decreased kidney gluconeogenesis, and blunted counter-regulatory response. We conducted a prospective observational study of hypoglycemia among 105 individuals with type 2 diabetes treated with insulin or a sulfonylurea using continuous glucose monitors. Design, setting, participants & measurements: We enrolled 81 participants with CKD, defined as eGFR<60 ml/min per 1.73 m 2, and 24 control participants with eGFR≥60 ml/min per 1.73 m 2 frequency-matched on age, duration of diabetes, hemoglobin A1c, and glucose-lowering medications. Each participant wore a continuous glucose monitor for two 6-day periods. We examined rates of sustained level 1 hypoglycemia (<70 mg/dl) and level 2 hypoglycemia (<54 mg/dl) among participants with CKD. We then tested differences compared with control participants as well as a second control population (n=73) using Poisson and linear regression, adjusting for age, sex, and race. Results: Over 890 total days of continuous glucose monitoring, participants with CKD were observed to have 255 episodes of level 1 hypoglycemia, of which 68 episodes reached level 2 hypoglycemia. Median rate of hypoglycemic episodes was 5.3 (interquartile range, 0.0–11.7) per 30 days and mean time spent in hypoglycemia was 28 (SD 37) minutes per day. Hemoglobin A1c and the glucose management indicator were the main clinical correlates of time in hypoglycemia (adjusted differences 6 [95% confidence interval, 2 to 10] and 13 [95% confidence interval, 7 to 20] fewer minutes per day per 1% higher hemoglobin A1c or glucose management indicator, respectively). Compared with control populations, participants with CKD were not observed to have significant differences in time in hypoglycemia (adjusted differences 4 [95% confidence interval, −12 to 20] and −12 [95% confidence interval, −29 to 5] minutes per day). Conclusions: Among people with type 2 diabetes and moderate to severe CKD, hypoglycemia was common, particularly with tighter glycemic control, but not significantly different from groups with similar clinical characteristics and preserved eGFR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationSevere hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471 · cited 1×
“Demographics Age (years) 69 (10) 64 (10) 59 (10) Men 52 (64) 15 (62) 43 (59) Race/ethnicity White 60 (74) 20 (83) NA Black 12 (15) 2 (8) NA Other 9 (11) 2 (8) NA Hispanic ethnicity 8 (10) 3 (12) NA Highest level of education High school 22 (27) 7 (29) NA Trade school 17 (21) 7 (29) NA College 23 (28) 7 (29) NA Graduat…”
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 4×
“Demographics Age (years) 69 (10) 64 (10) 59 (10) Men 52 (64) 15 (62) 43 (59) Race/ethnicity White 60 (74) 20 (83) NA Black 12 (15) 2 (8) NA Other 9 (11) 2 (8) NA Hispanic ethnicity 8 (10) 3 (12) NA Highest level of education High school 22 (27) 7 (29) NA Trade school 17 (21) 7 (29) NA College 23 (28) 7 (29) NA Graduat…”
BackgroundInfluentialBonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684 · cited 2×
“180 mg/dl), coefficient of variation (SD divided by mean of all CGM glucose concentrations, a preferred metric of glycemic variability), SD and interquartile range of all CGM glucose concentrations (alternative variability metrics), and the glucose management indicator (GMI) (a measure of mean blood glucose calculated…”
BackgroundGlycemic Variability: A Hemoglobin A1c–Independent Risk Factor for Diabetic Complications
Brownlee, M., & Hirsch, I. B. (2006) · JAMA · doi:10.1001/jama.295.14.1707 · Cited by 482
Self-citationMiller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429 · cited 7×
“02 10 PM–10 AM 23 (32) 22 (29) 39 (63) 10 AM–10 PM 5 (11) 7 (13) 10 (21) Time ,54 mg/dl 6 (12) 9 (15) 13 (29) Time in range, min 70–180 mg/dl per d 886 (325) 998 (312) 0.”
BackgroundInfluentialFrequency of hypoglycemia and its significance in chronic kidney disease
Moen, M. F., Zhan, M., Hsu, V. D., Walker, L. D., Einhorn, L. M., Seliger, S. L., & Fink, J. C. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00800209 · Cited by 423 · cited 4×
“CKD has also been associated with severe hypoglycemia in other studies (4,14), but the full burden of hypoglycemia among people with type 2 diabetes and CKD, including asymptomatic episodes, is not well defined.”
BackgroundInfluentialPapademetriou, V., Lovato, L., Doumas, M., Nylen, E., Mottl, A., Cohen, R. M., Applegate, W. B., Puntakee, Z., Yale, J. F., & Cushman, W. C. (2015) · Kidney International · doi:10.1038/ki.2014.296 · Cited by 210
Cited by
Mayeda, L., Katz, R., Ahmad, I., Bansal, N., Batacchi, Z., Hirsch, I. B., Robinson, N., Trence, D. L., Zelnick, L., & de Boer, I. H. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000991 · Cited by 162
Self-citationZelnick, L. R., Batacchi, Z. O., Ahmad, I., Dighe, A., Little, R. R., Trence, D. L., Hirsch, I. B., & de Boer, I. H. (2020) · Diabetes Care · doi:10.2337/dc20-0915 · Cited by 55
Self-citationDavis, T. M. E., Dwyer, P., England, M., Fegan, P. G., & Davis, W. A. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0331 · Cited by 31
“However, there could be other specific categories of hypoglycemia-prone insulin-treated individuals, such as those with very frequent episodes 21 or those with chronic kidney disease, 22 who might benefit from access to isCGM for hypoglycemia prevention.”
Kawahara, T., Tsuji, M., Tominaga, N., Toyama, N., & Toda, M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac119 · Cited by 13
“Some [45, 46] but not all [47] previous studies have noted such an association.”
Result
Metadata
- Authors
- Ahmad, I., Zelnick, L. R., Batacchi, Z., Robinson, N., Dighe, A., Manski-Nankervis, J.-A. E., Furler, J., O’Neal, D. N., Little, R., Trence, D., Hirsch, I. B., Bansal, N., & de Boer, I. H.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2019-04-17
- Volume
- 14
- Issue
- 6
- Pages
- 844-853
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- OpenAlex
- W2937001530
- Cited by
- 49
- References
- 11
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.